Brokerages forecast that Intersect ENT Inc (NASDAQ:XENT) will post earnings per share of ($0.40) for the current quarter, according to Zacks. Five analysts have issued estimates for Intersect ENT’s earnings, with estimates ranging from ($0.46) to ($0.33). Intersect ENT reported earnings per share of ($0.25) during the same quarter last year, which suggests a negative year-over-year growth rate of 60%. The company is scheduled to issue its next earnings results on Monday, November 4th.

According to Zacks, analysts expect that Intersect ENT will report full-year earnings of ($1.44) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.32). For the next year, analysts expect that the business will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.43) to ($1.10). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Intersect ENT.

Intersect ENT (NASDAQ:XENT) last released its earnings results on Thursday, August 1st. The medical equipment provider reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.02). Intersect ENT had a negative net margin of 31.43% and a negative return on equity of 29.16%. The business had revenue of $26.66 million during the quarter, compared to the consensus estimate of $27.13 million. During the same quarter in the prior year, the firm earned ($0.14) EPS. The business’s revenue was up 1.4% on a year-over-year basis.

XENT has been the topic of a number of recent analyst reports. Northland Securities upgraded Intersect ENT from an “under perform” rating to a “market perform” rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. Berenberg Bank cut Intersect ENT from a “buy” rating to a “hold” rating and decreased their target price for the company from $35.00 to $27.00 in a research report on Friday, June 21st. BidaskClub upgraded Intersect ENT from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 4th. ValuEngine upgraded Intersect ENT from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Piper Jaffray Companies cut Intersect ENT from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $30.00 to $17.00 in a research report on Friday, August 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $27.11.

Intersect ENT stock traded up $0.19 during midday trading on Friday, reaching $17.86. The company’s stock had a trading volume of 291,000 shares, compared to its average volume of 382,092. Intersect ENT has a 52 week low of $15.01 and a 52 week high of $35.87. The business has a 50-day moving average price of $17.04 and a 200-day moving average price of $24.91. The stock has a market cap of $556.13 million, a PE ratio of -23.50 and a beta of 0.73.

Large investors have recently added to or reduced their stakes in the company. Quantamental Technologies LLC grew its holdings in shares of Intersect ENT by 211.0% during the first quarter. Quantamental Technologies LLC now owns 1,950 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 1,323 shares during the last quarter. William Blair Investment Management LLC grew its holdings in shares of Intersect ENT by 35.6% during the first quarter. William Blair Investment Management LLC now owns 528,404 shares of the medical equipment provider’s stock worth $16,988,000 after purchasing an additional 138,780 shares during the last quarter. Boston Advisors LLC grew its holdings in shares of Intersect ENT by 8.9% during the second quarter. Boston Advisors LLC now owns 39,535 shares of the medical equipment provider’s stock worth $900,000 after purchasing an additional 3,230 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Intersect ENT by 434.9% during the second quarter. Jennison Associates LLC now owns 469,658 shares of the medical equipment provider’s stock worth $10,689,000 after purchasing an additional 381,857 shares during the last quarter. Finally, Xact Kapitalforvaltning AB bought a new stake in shares of Intersect ENT during the first quarter worth about $212,000. Institutional investors own 97.75% of the company’s stock.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Featured Story: Why is the conference call important?

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.